Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nafarelin
Drug ID BADD_D01513
Description Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
Indications and Usage For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.
Marketing Status Prescription
ATC Code H01CA02
DrugBank ID DB00666
KEGG ID D08241
MeSH ID D017274
PubChem ID 25077405
TTD Drug ID D08WYM
NDC Product Code Not Available
Synonyms Nafarelin | Synarel | RS-94991-298 | RS 94991 298 | RS94991298 | Nafarelin Acetate | Nafarelin Acetate, Hydrate | Nafarelin Monoacetate
Chemical Information
Molecular Formula C66H83N17O13
CAS Registry Number 76932-56-4
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C 2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=C N7)NC(=O)C8CCC(=O)N8
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Epistaxis24.07.01.005; 22.04.03.001--
Erythema nodosum23.07.02.001; 10.02.01.0200.005881%Not Available
Eye pain06.08.03.002--
Gastritis07.08.02.001--
Gynaecomastia21.05.04.003; 05.05.02.003--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Herpes simplex23.09.03.001; 11.05.02.001--Not Available
High density lipoprotein decreased13.12.01.003--Not Available
Hirsutism23.02.04.001; 05.05.01.005--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypovolaemia14.05.05.002--Not Available
IIIrd nerve paralysis17.04.02.003; 06.05.02.011--Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Libido increased21.03.02.007; 19.08.03.002--
Loss of libido19.08.03.003--Not Available
Menopausal symptoms21.02.02.002--Not Available
Menopause26.03.01.001--Not Available
Menorrhagia21.01.03.002--
Menstrual disorder21.01.01.004--Not Available
Mood swings19.04.03.001--Not Available
Mucous membrane disorder08.01.06.004--Not Available
Multiple pregnancy18.08.03.001--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal dryness22.04.03.002--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages